Particle.news

UCSF Confirms Gut Microbiome's Role in Reducing Chemotherapy Toxicity

New studies reveal specific gut bacteria detoxify fluoropyrimidine drugs and produce vitamin K2, offering potential for personalized cancer care.

Overview

  • Researchers at UCSF identified gut bacteria capable of detoxifying fluoropyrimidine chemotherapy drugs by transforming them into harmless byproducts.
  • The presence of these drug-metabolizing bacteria correlates with reduced side effect severity, such as nausea and vomiting, in colorectal cancer patients.
  • Preclinical mouse studies showed that administering these bacteria as probiotics significantly alleviated chemotherapy-induced side effects.
  • A nonpathogenic strain of E. coli thriving during chemotherapy produces vitamin K2, which was found to reduce neuropathic symptoms in treated mice.
  • Efforts are underway to integrate microbiome profiling and targeted interventions into clinical oncology to personalize treatment and improve patient outcomes.